ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Metagenomi Inc

Metagenomi Inc (MGX)

2.11
0.14
(7.11%)
Closed 02 November 7:00AM
2.1485
0.0385
(1.82%)
After Hours: 8:21AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
2.1485
Bid
2.01
Offer
2.14
Volume
130,256
1.97 Day's Range 2.16
1.85 52 Week Range 12.74
Market Cap
Previous Close
1.97
Open
1.97
Last Trade Time
Financial Volume
US$ 266,466
VWAP
2.0457
Average Volume (3m)
236,041
Shares Outstanding
37,428,994
Dividend Yield
-
PE Ratio
-1.15
Earnings Per Share (EPS)
-1.82
Revenue
44.76M
Net Profit
-68.26M

About Metagenomi Inc

At Metageno­mi, we are cre­at­ing poten­tial­ly cura­tive ther­a­peu­tics using our metage­­nomics-pow­ered genome edit­ing toolbox.We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of geno... At Metageno­mi, we are cre­at­ing poten­tial­ly cura­tive ther­a­peu­tics using our metage­­nomics-pow­ered genome edit­ing toolbox.We believe tools with capa­bil­i­ties that go beyond the cur­rent tech­nol­o­gy land­scape will be required in order to reach the full ther­a­peu­tic poten­tial of genome edit­ing. By har­ness­ing the pow­er of metage­nomics, the study of genomes recov­ered from uncul­ti­vat­ed organ­isms in the nat­ur­al envi­ron­ment, we are dis­cov­er­ing and devel­op­ing a suite of nov­el genome edit­ing tools with the poten­tial to make any desired ther­a­peu­tic gene edit, any­where in the human genome. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Metagenomi Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MGX. The last closing price for Metagenomi was US$1.97. Over the last year, Metagenomi shares have traded in a share price range of US$ 1.85 to US$ 12.74.

Metagenomi currently has 37,428,994 shares in issue. The market capitalisation of Metagenomi is US$73.74 million. Metagenomi has a price to earnings ratio (PE ratio) of -1.15.

MGX Latest News

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 31, 2024 NEW...

Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Oct. 28, 2024 NEW YORK, Oct. 28, 2024...

Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated...

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 17, 2024 NEW...

Metagenomi Presents Compact SMART Editing PlatformΒ at AIChE 7th International Conference on CRISPR Technologies

Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing...

Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX

Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Oct. 14, 2024 NEW YORK, Oct. 14, 2024 /PRNewswire/...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX PR Newswire NEW YORK, Oct. 10, 2024 NEW YORK, Oct. 10, 2024 /PRNewswire/...

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 7, 2024 NEW YORK, Oct. 7, 2024 /PRNewswire/...

Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX

Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Sept. 30, 2024 NEW YORK, Sept. 30, 2024 /PRNewswire/...

Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.14857.42522.171.922824172.01096565CS
40.04852.309523809522.12.171.852662591.97191973CS
12-1.2515-36.80882352943.43.631.852360412.28368703CS
26-4.8715-69.39458689467.028.17471.851526543.13242068CS
52-8.1015-79.039024390210.2512.741.851645075.78619051CS
156-8.1015-79.039024390210.2512.741.851645075.78619051CS
260-8.1015-79.039024390210.2512.741.851645075.78619051CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
US$ 4.98
(149.00%)
68.46M
INVZWInnoviz Technologies Ltd
US$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
US$ 5.87
(68.19%)
37.58M
ATHAAthira Pharma Inc
US$ 0.606
(41.56%)
236.07M
TILEInterface Inc
US$ 23.24
(33.03%)
2.12M
EPIXESSA Pharma Inc
US$ 1.45
(-72.12%)
34.3M
ELABElevai Labs Inc
US$ 0.0288
(-51.19%)
202.28M
OSTOstin Technology Group Company Ltd
US$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
US$ 1.23
(-36.92%)
21M
VCIGVCI Global Ltd
US$ 0.0583
(-27.58%)
26.57M
ATHAAthira Pharma Inc
US$ 0.606
(41.56%)
236.07M
SQQQProShares UltraPro Short QQQ
US$ 7.44
(-2.11%)
214.96M
NVDANVIDIA Corporation
US$ 135.40
(1.99%)
206.38M
ELABElevai Labs Inc
US$ 0.0288
(-51.19%)
201.61M
INTCIntel Corporation
US$ 23.20
(7.81%)
171.4M